Mercaptoethylguanidine inhibits the inflammatory response in a murine model of chronic infection with Pseudomonas aeruginosa

Robert W. Wilmott, Joseph A. Kitzmiller, Csaba Szabo, Garry J. Southan, Andrew L. Salzman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Chronic airway inflammation induced by Pseudomonas aeruginosa is the eventual cause of respiratory failure in most people affected by cystic fibrosis. Recent evidence implicates the involvement of free radical and oxidant stress in the pathogenesis of the inflammatory injury. Here we report the efficacy of a novel experimental therapeutic, mercaptoethylguanidine (MEG), which has combined actions as a selective inhibitor of the inducible nitric oxide synthase and as a scavenger of peroxynitrite, a potent oxidant formed in the reaction of nitric oxide and superoxide radical. Chronic pulmonary infection was established in FVB/N mice by intratracheal administration of 105 colony-forming units of P. aeruginosa in agar beads. Treatment with MEG (10 mg/kg/dose every 8 h i.p.) inhibited weight loss in the first 3 days and reduced histologic injury at 8 days postinfection. MEG also reduced myeloperoxidase activity, a marker of neutrophil infiltration, at 8 days and concentrations of the proinflammatory cytokines interleukin- 1β, tumor necrosis factor-α, and macrophage inflammatory protein 2 in whole lung homogenates. MEG-treated animals and controls had similar perioperative mortality and comparable colony counts of P. aeruginosa at 8 days, indicating that MEG did not exacerbate infection. Our data suggest that MEG may be an effective immunomodulatory therapy of pulmonary inflammation induced by chronic infection.

Original languageEnglish (US)
Pages (from-to)88-95
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume292
Issue number1
StatePublished - Jan 2000
Externally publishedYes

Fingerprint

Pseudomonas aeruginosa
Infection
Oxidants
Chemokine CXCL2
Lung
Peroxynitrous Acid
Immunomodulation
Neutrophil Infiltration
Wounds and Injuries
Nitric Oxide Synthase Type II
Interleukin-1
Cystic Fibrosis
Superoxides
Respiratory Insufficiency
Peroxidase
Agar
Free Radicals
2-mercaptoethylguanidine
Weight Loss
Pneumonia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Mercaptoethylguanidine inhibits the inflammatory response in a murine model of chronic infection with Pseudomonas aeruginosa. / Wilmott, Robert W.; Kitzmiller, Joseph A.; Szabo, Csaba; Southan, Garry J.; Salzman, Andrew L.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 292, No. 1, 01.2000, p. 88-95.

Research output: Contribution to journalArticle

Wilmott, Robert W. ; Kitzmiller, Joseph A. ; Szabo, Csaba ; Southan, Garry J. ; Salzman, Andrew L. / Mercaptoethylguanidine inhibits the inflammatory response in a murine model of chronic infection with Pseudomonas aeruginosa. In: Journal of Pharmacology and Experimental Therapeutics. 2000 ; Vol. 292, No. 1. pp. 88-95.
@article{bfe76f8e94a14c508b19483abf642395,
title = "Mercaptoethylguanidine inhibits the inflammatory response in a murine model of chronic infection with Pseudomonas aeruginosa",
abstract = "Chronic airway inflammation induced by Pseudomonas aeruginosa is the eventual cause of respiratory failure in most people affected by cystic fibrosis. Recent evidence implicates the involvement of free radical and oxidant stress in the pathogenesis of the inflammatory injury. Here we report the efficacy of a novel experimental therapeutic, mercaptoethylguanidine (MEG), which has combined actions as a selective inhibitor of the inducible nitric oxide synthase and as a scavenger of peroxynitrite, a potent oxidant formed in the reaction of nitric oxide and superoxide radical. Chronic pulmonary infection was established in FVB/N mice by intratracheal administration of 105 colony-forming units of P. aeruginosa in agar beads. Treatment with MEG (10 mg/kg/dose every 8 h i.p.) inhibited weight loss in the first 3 days and reduced histologic injury at 8 days postinfection. MEG also reduced myeloperoxidase activity, a marker of neutrophil infiltration, at 8 days and concentrations of the proinflammatory cytokines interleukin- 1β, tumor necrosis factor-α, and macrophage inflammatory protein 2 in whole lung homogenates. MEG-treated animals and controls had similar perioperative mortality and comparable colony counts of P. aeruginosa at 8 days, indicating that MEG did not exacerbate infection. Our data suggest that MEG may be an effective immunomodulatory therapy of pulmonary inflammation induced by chronic infection.",
author = "Wilmott, {Robert W.} and Kitzmiller, {Joseph A.} and Csaba Szabo and Southan, {Garry J.} and Salzman, {Andrew L.}",
year = "2000",
month = "1",
language = "English (US)",
volume = "292",
pages = "88--95",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Mercaptoethylguanidine inhibits the inflammatory response in a murine model of chronic infection with Pseudomonas aeruginosa

AU - Wilmott, Robert W.

AU - Kitzmiller, Joseph A.

AU - Szabo, Csaba

AU - Southan, Garry J.

AU - Salzman, Andrew L.

PY - 2000/1

Y1 - 2000/1

N2 - Chronic airway inflammation induced by Pseudomonas aeruginosa is the eventual cause of respiratory failure in most people affected by cystic fibrosis. Recent evidence implicates the involvement of free radical and oxidant stress in the pathogenesis of the inflammatory injury. Here we report the efficacy of a novel experimental therapeutic, mercaptoethylguanidine (MEG), which has combined actions as a selective inhibitor of the inducible nitric oxide synthase and as a scavenger of peroxynitrite, a potent oxidant formed in the reaction of nitric oxide and superoxide radical. Chronic pulmonary infection was established in FVB/N mice by intratracheal administration of 105 colony-forming units of P. aeruginosa in agar beads. Treatment with MEG (10 mg/kg/dose every 8 h i.p.) inhibited weight loss in the first 3 days and reduced histologic injury at 8 days postinfection. MEG also reduced myeloperoxidase activity, a marker of neutrophil infiltration, at 8 days and concentrations of the proinflammatory cytokines interleukin- 1β, tumor necrosis factor-α, and macrophage inflammatory protein 2 in whole lung homogenates. MEG-treated animals and controls had similar perioperative mortality and comparable colony counts of P. aeruginosa at 8 days, indicating that MEG did not exacerbate infection. Our data suggest that MEG may be an effective immunomodulatory therapy of pulmonary inflammation induced by chronic infection.

AB - Chronic airway inflammation induced by Pseudomonas aeruginosa is the eventual cause of respiratory failure in most people affected by cystic fibrosis. Recent evidence implicates the involvement of free radical and oxidant stress in the pathogenesis of the inflammatory injury. Here we report the efficacy of a novel experimental therapeutic, mercaptoethylguanidine (MEG), which has combined actions as a selective inhibitor of the inducible nitric oxide synthase and as a scavenger of peroxynitrite, a potent oxidant formed in the reaction of nitric oxide and superoxide radical. Chronic pulmonary infection was established in FVB/N mice by intratracheal administration of 105 colony-forming units of P. aeruginosa in agar beads. Treatment with MEG (10 mg/kg/dose every 8 h i.p.) inhibited weight loss in the first 3 days and reduced histologic injury at 8 days postinfection. MEG also reduced myeloperoxidase activity, a marker of neutrophil infiltration, at 8 days and concentrations of the proinflammatory cytokines interleukin- 1β, tumor necrosis factor-α, and macrophage inflammatory protein 2 in whole lung homogenates. MEG-treated animals and controls had similar perioperative mortality and comparable colony counts of P. aeruginosa at 8 days, indicating that MEG did not exacerbate infection. Our data suggest that MEG may be an effective immunomodulatory therapy of pulmonary inflammation induced by chronic infection.

UR - http://www.scopus.com/inward/record.url?scp=0033957540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033957540&partnerID=8YFLogxK

M3 - Article

C2 - 10604934

AN - SCOPUS:0033957540

VL - 292

SP - 88

EP - 95

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -